Top

Published in:

Open Access 01-10-2019 | Myocardial Infarction | Review

Novel uses of thyroid hormones in cardiovascular conditions

Author: Salman Razvi

Published in: Endocrine | Issue 1/2019

Abstract

Thyroid hormone levels are reduced in cardiovascular diseases and this phenomenon is associated with worse outcomes. It is unclear whether the changes in thyroid hormone bioavailability to the affected myocardium are beneficial or if this is a maladaptive response. Experimental studies from animal models of acute myocardial infarction (AMI) suggest that thyroid hormone treatment may be beneficial. There is limited data available on the use of thyroid hormones in patients with AMI and heart failure and this suggests that treatment to normalise thyroid hormone levels may be safe and potentially efficacious. Similarly, evidence of thyroid hormone therapy in patients undergoing cardiac surgery or during cardiac transplantation is limited. It is therefore difficult to draw any firm conclusions about benefits or risks of thyroid hormone treatment in these conditions. Large scale clinical trials of thyroid hormones in patients with cardiac conditions are required to confirm safety and evaluate efficacy. Furthermore, it needs to be elucidated which hormone to administer (thyroxine or triiodothyronine), when in the disease pathway to treat, dose of thyroid hormone to administer, and which parameters to utilise to assess safety and efficacy. Until these important questions are answered thyroid hormone therapy in cardiovascular diseases must remain within the research domain.

G.A. Roth, C. Johnson, A. Abajobir et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017). https://doi.org/10.1016/j.jacc.2017.04.052 CrossRefPubMedPubMedCentral

V.L. Roger, Epidemiology of heart failure. Circ. Res. 1136, 646–659 (2013). https://doi.org/10.1161/circresaha.113.300268 CrossRef

A. Jabbar, A. Pingitore, S.H. Pearce et al. Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol. 14, 39–55 (2017). https://doi.org/10.1038/nrcardio.2016.174 CrossRefPubMed

P.N. Taylor, S. Razvi, S.H. Pearce, C.M. Dayan, Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J. Clin. Endocrinol. Metab. 98, 3562–3571 (2013). https://doi.org/10.1210/jc.2013-1315 CrossRefPubMed

E.M. Kaptein, A. Sanchez, E. Beale, L.S. Chan, Clinical review: thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis. J. Clin. Endocrinol. Metab. 95, 4526–4534 (2010). https://doi.org/10.1210/jc.2010-1052 CrossRefPubMed

S. Razvi, A. Jabbar, A. Pingitore et al. Thyroid hormones and cardiovascular function and diseases. J. Am. Coll. Cardiol. 71, 1781–1796 (2018). https://doi.org/10.1016/j.jacc.2018.02.045 CrossRefPubMed

G.R. Murray, Note on the treatment of myxoedema by hypodermic injections of an extract of the thyroid gland of a sheep. Br. Med. J. 2, 796–797 (1891). https://doi.org/10.1136/bmj.2.1606.796 CrossRefPubMedPubMedCentral

G.R. Murray, The life-history of the first case of myxoedema treated by thyroid extract. Br. Med. J. 13, 359–360 (1920). https://doi.org/10.1136/bmj.1.3089.359 CrossRef

J. Lindholm, P. Laurberg, Hypothyroidism and thyroid substitution: historical aspects. J. Thyroid Res. 2011, 809341 (2011). https://doi.org/10.4061/2011/809341 CrossRefPubMedPubMedCentral

10.

J. Gross, R. Pitt-Rivers, The identification of 3:5:3”-L-triiodothyronine in human plasma. Lancet 1, 439–441 (1952). https://doi.org/10.1016/s0140-6736(52)91952-1 CrossRefPubMed

11.

F.D. Hart, N.F. Maclagan, Oral thyroxine in the treatment of myxoedema. Br. Med. J. 1, 512–518 (1950). https://doi.org/10.1136/bmj.1.4652.512 CrossRefPubMedPubMedCentral

12.

S.R. Smith, Desiccated thyroid preparations. Obsolete therapy. Arch. Intern. Med. 144, 926–927 (1984).CrossRef

13.

E. Kirk, M. Chieffi, W.B. Kountz, The correlation between thyroid function and the incidence of atherosclerosis. J. Gerontol. 4, 212–217 (1949).CrossRef

14.

I.A. Gaspar, Postmortem observations on the thyroid in atherosclerosis. J. Am. Geriatr. Soc. 16, 686–695 (1968). https://doi.org/10.1111/j.1532-5415.1968.tb01278.x CrossRefPubMed

15.

J.H. Moyer, A current appraisal of drug therapy of atherosclerosis. Arch. Environ. Health 14, 337–347 (1967).CrossRef

16.

The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA 220, 996–1008 (1972).CrossRef

17.

J.P. Bantle, D.B. Hunninghake, I.D. Frantz et al. Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia. Am. J. Med. 77, 475–481 (1984). https://doi.org/10.1016/0002-9343(84)90107-4 CrossRefPubMed

18.

W.F. Young Jr., C.A. Gorman, N.S. Jiang et al. L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect. Clin. Pharmacol. Ther. 36, 781–787 (1984). https://doi.org/10.1038/clpt.1984.257 CrossRefPubMed

19.

N. Rodondi, W.P. den Elzen, D.C. Bauer et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304, 1365–1374 (2010). https://doi.org/10.1001/jama.2010.1361 CrossRefPubMedPubMedCentral

20.

T.H. Collet, J. Gussekloo, D.C. Bauer et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 172, 799–809 (2012). https://doi.org/10.1001/archinternmed.2012.402 CrossRefPubMed

21.

B. Gencer, T.H. Collet, V. Virgini et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 126, 1040–1049 (2012). https://doi.org/10.1161/CIRCULATIONAHA.112.096024 CrossRefPubMed

22.

B. Gereben, A.M. Zavacki, S. Ribich et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr. Rev. 29, 898–938 (2008). https://doi.org/10.1210/er.2008-0019 CrossRefPubMedPubMedCentral

23.

W. Croteau, J.C. Davey, V.A. Galton, D.L. St Germain, Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. J. Clin. Investig. 98, 405–417 (1996). https://doi.org/10.1172/JCI118806 CrossRefPubMed

24.

D. Salvatore, T. Bartha, J.W. Harney, P.R. Larsen, Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137, 3308–3315 (1996). https://doi.org/10.1210/endo.137.8.8754756 CrossRefPubMed

25.

G.A. Brent, The molecular basis of thyroid hormone action. N. Engl. J. Med. 331, 847–853 (1994). https://doi.org/10.1056/NEJM199409293311306 CrossRefPubMed

26.

B.D. Hoit, S.F. Khoury, Y. Shao et al. Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Circulation 96, 592–598 (1997). https://doi.org/10.1161/01.cir.96.2.592 CrossRefPubMed

27.

I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344, 501–509 (2001). https://doi.org/10.1056/NEJM200102153440707 CrossRefPubMed

28.

W.S. Simonides, M.A. Mulcahey, E.M. Redout et al. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J. Clin. Investig. 118, 975–983 (2008). https://doi.org/10.1172/JCI32824 CrossRefPubMed

29.

I. Mourouzis, F. Forini, C. Pantos, G. Iervasi, Thyroid hormone and cardiac disease: from basic concepts to clinical application. J. Thyroid Res. 2011, 958626 (2011). https://doi.org/10.4061/2011/958626 CrossRefPubMedPubMedCentral

30.

C. Pantos, I. Mourouzis, D.V. Cokkinos, New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail. Rev. 16, 79–96 (2011). https://doi.org/10.1007/s10741-010-9185-3 CrossRefPubMed

31.

Y.K. Lee, K.M. Ng, Y.C. Chan et al. Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. Mol. Endocrinol. 24, 1728–1736 (2010). https://doi.org/10.1210/me.2010-0032 CrossRefPubMedPubMedCentral

32.

S. Chen, A. Shauer, D.R. Zwas, C. Lotan, A. Keren, I. Gotsman, The effect of thyroid function on clinical outcome in patients with heart failure. Eur. J. Heart Fail. 16, 217–226 (2014). https://doi.org/10.1002/ejhf.42 CrossRefPubMed

33.

J.E. Mitchell, A.S. Hellkamp, D.B. Mark et al. Thyroid function in heart failure and impact on mortality. JACC Heart Fail. 1, 48–55 (2013). https://doi.org/10.1016/j.jchf.2012.10.004 CrossRefPubMedPubMedCentral

34.

G. Iervasi, A. Pingitore, P. Landi et al. Low-T3 syndrome. A strong prognostic predictor of death in patients with heart disease. Circulation 107, 708–713 (2003). https://doi.org/10.1161/01.cir.0000048124.64204.3f CrossRefPubMed

35.

L. Wartofsky, K.D. Burman, Alteration in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr. Rev. 3, 164–217 (1982). https://doi.org/10.1210/edrv-3-2-164 CrossRefPubMed

36.

R.P. Peeters, P.J. Wouters, E. Kaptein et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J. Clin. Endocrinol. Metab. 88, 3202–3211 (2003). https://doi.org/10.1210/jc.2002-022013 CrossRefPubMed

37.

I.J. Chopra, S.Y. Wu, G.N. Teco, F. Santini, A radioimmunoassay for measurement of 3,5,3′-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J. Clin. Endocrinol. Metab. 75, 189–194 (1992). https://doi.org/10.1210/jcem.75.1.1619009 CrossRefPubMed

38.

L.H. Duntas, T.T. Nguyen, F.S. Keck et al. Changes in metabolism of TRH in euthyroid sick syndrome. Eur. J. Endocrinol. 141, 337–341 (1999).CrossRef

39.

A. Boelen, M.C. Platvoet-Ter Schiphorst, W.M. Wiersinga, Association between serum interleukin-6 and serum 3, 5, 3′- triiodothyronine in nonthyroidal illness. J. Clin. Endocrinol. Metab. 77, 1695–1699 (1993). https://doi.org/10.1210/jcem.77.6.8263160 CrossRefPubMed

40.

J.M. Stouthard, T.Van der Poll, E. Ebdert, et al. Effects of acute and chronic IL-6 administration on thyroid hormone metabolism in humans. J. Clin. Endocrinol. Metab. 79, 1342–1346 (1994). https://doi.org/10.1210/jcem.79.5.7962327 CrossRefPubMed

41.

L. Bartalena, F. Bogazzi, S. Brogioni et al. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur. J. Endocrinol. 138, 603–614 (1998).CrossRef

42.

T. Kimura, T. Kanda, N. Kotajima et al. Involvement of circulating IL-6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. Eur. J. Endocrinol. 143, 179–184 (2000).CrossRef

43.

C. Sylvén, E. Jansson, P. Sotonyi et al. Cardiac nuclear hormone receptor mRNA in heart failure in man. Life Sci. 59, 1917–1922 (1996). https://doi.org/10.1016/s0024-3205(96)00539-5 CrossRefPubMed

44.

K. Kinugawa, K. Yonekura, R.C. Ribeiro et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ. Res. 89, 591–598 (2001). https://doi.org/10.1161/hh1901.096706 CrossRefPubMed

45.

Y. Liu, R.A. Redetzke, S. Said et al. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am. J. Physiol. Heart Circ. Physiol. 294, H2137–H2143 (2008). https://doi.org/10.1152/ajpheart.01379.2007 CrossRefPubMed

46.

P. Moruzzi, E. Doria, P.G. Agostoni et al. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 73, 374–378 (1994). https://doi.org/10.1016/0002-9149(94)90011-6 CrossRefPubMed

47.

P. Moruzzi, E. Doria, P.G. Agostoni, Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am. J. Med. 101, 461–467 (1996). https://doi.org/10.1016/s0002-9343(96)00281-1 CrossRefPubMed

48.

M.A. Hamilton, L.W. Stevenson, G.C. Fonarow et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am. J. Cardiol. 81, 443–447 (1998). https://doi.org/10.1016/s0002-9149(97)00950-8 CrossRefPubMed

49.

A. Pingitore, E. Galli, A. Barison et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 1351–1358 (2008). https://doi.org/10.1210/jc.2007-2210 CrossRefPubMed

50.

P. Holmager, U. Schmidt, P. Mark et al. Long-term L-triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised double-blind, cross-over, placebo-controlled intervention study. Clin. Endocrinol. 83, 931–937 (2015). https://doi.org/10.1111/cen.12648 CrossRef

51.

A. Amin, M. Chitsazan, S. Taghavi, M. Ardeshiri, Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low-triiodothyronine syndrome: a randomized, double-blind, placebo-controlled study. ESC Heart Fail. 2, 5–11 (2015). https://doi.org/10.1002/ehf2.12025 CrossRefPubMedPubMedCentral

52.

A. Pingitore, G. Nicolini, C. Kusmic et al. Cardioprotection and thyroid hormones. Heart Fail. Rev. 21, 391–399 (2016). https://doi.org/10.1007/s10741-016-9545-8 CrossRefPubMed

53.

C.J. Pol, A. Muller, M.J. Zuidwijk et al. Left-ventricular remodelling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition. Endocrinology 152, 669–679 (2011). https://doi.org/10.1210/en.2010-0431 CrossRefPubMed

54.

Y. Song, J. Li, S. Bian et al. Association between low free triiodothyronine levels and poor prognosis in patients with acute ST-elevation myocardial infarction. Biomed. Res. Int. 2018, 9803851 (2018). https://doi.org/10.1155/2018/9803851 CrossRefPubMedPubMedCentral

55.

G. Iervasi, S. Molinaro, P. Landi et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch. Intern. Med. 167, 1526–1532 (2007). https://doi.org/10.1001/archinte.167.14.1526 CrossRefPubMed

56.

V. Rajagopalan, Y. Zhang, C. Pol et al. Modified low-dose triiodo-L-thyronine therapy safely improves function following myocardial ischemia-reperfusion injury. Front. Phsyiol. 8, 225 (2017). https://doi.org/10.3389/fphys.2017.00225 CrossRef

57.

K.K. Henderson, S. Danzi, J.T. Paul et al. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ. Heart Fail. 2, 243–252 (2009). https://doi.org/10.1161/CIRCHEARTFAILURE.108.810747 CrossRefPubMed

58.

M.D. Files, M. Kajimoto, C.M. O’Kelly Priddy et al. Triiodothyronine facilitates weaning from extracorporeal membrane oxygenation by improved mitochondrial substrate utilization. J. Am. Heart Assoc. 3, e000680 (2014). https://doi.org/10.1161/JAHA.113.000680 CrossRefPubMedPubMedCentral

59.

R. Lesmana, R.A. Sinha, B.K. Singh et al. Thyroid hormone stimulation of autophagy is essential for mitochondrial biogenesis and activity in skeletal muscle. Endocrinology 157, 23–38 (2016). https://doi.org/10.1210/en.2015-1632 CrossRefPubMed

60.

E. Yehuda-Shnaidman, B. Kalderon, N. Azazmeh, J. Bar-Tana, Gating of the mitochondrial permeability transition pore by thyroid hormone. FASEB J. 24, 93–104 (2010). https://doi.org/10.1096/fj.09-133538 CrossRefPubMed

61.

N.Y. Weltman, K. Ojamaa, E.H. Schlenker et al. Low-dose T3 replacement restores depressed cardiac T3 levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus. Mol. Med. 20, 302–312 (2014). https://doi.org/10.2119/molmed.2013.00040 CrossRefPubMedPubMedCentral

62.

C. Pantos, I. Mourouzis, T. Saranteas et al. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res. Cardiol. 104, 69–77 (2009). https://doi.org/10.1007/s00395-008-0758-4 CrossRefPubMed

63.

K. Ojamaa, A. Kenessey, R. Shenoy, I. Klein, Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am. J. Physiol. Endocrinol. Metab. 279, E1319–E1324 (2000). https://doi.org/10.1152/ajpendo.2000.279.6.E1319 CrossRefPubMed

64.

C. Pantos, I. Mourouzis, K. Markakis et al. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur. J. Cardiothorac. Surg. 32, 333–339 (2007). https://doi.org/10.1016/j.ejcts.2007.05.004 CrossRefPubMed

65.

B. Wang, S. Liu, L. Li et al. Non-thyroidal illness syndrome in patients with cardiovascular diseases: a systematic review and meta-analysis. Int. J. Cardiol. 226, 1–10 (2017). https://doi.org/10.1016/j.ijcard.2016.10.039 CrossRefPubMed

66.

A. Pingitore, F. Mastorci, P. Piaggi et al. Usefulness of triiodothyronine replacement therapy in patients with ST elevation myocardial infarction and borderline/reduced triiodothyronine levels (from the THIRST study). Am. J. Cardiol. 123, 905–912 (2019). https://doi.org/10.1016/j.amjcard.2018.12.020 CrossRefPubMed

67.

A. Jabbar, L. Ingoe, S. Pearce et al. Thyroxine in acute myocardial infarction (ThyrAMI) – levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial. Trials 16, 115 (2015). https://doi.org/10.1186/s13063-015-0621-5 CrossRefPubMedPubMedCentral

68.

A.M. Ranasinghe, D.W. Quinn, D. Pagano et al. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation 114, I245–I250 (2006). https://doi.org/10.1161/CIRCULATIONAHA.105.000786 CrossRefPubMed

69.

J.Q. Zhang, Q.Y. Yang, F.S. Xue et al. Preoperative oral thyroid hormones to prevent euthyroid sick syndrome and attenuate myocardial ischemia-reperfusion injury after cardiac surgery with cardiopulmonary bypass in children: a randomized, double-blind, placebo-controlled trial. Medicine 97, e12100 (2018). https://doi.org/10.1097/MD.0000000000012100 CrossRefPubMedPubMedCentral

70.

M.A. Portman, A. Slee, A.K. Olson et al. TRICC Investigators. Triiodothyronine supplementation in infants and children undergoing cardiopulmonary bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis. Circulation 122, S224–S233 (2010). https://doi.org/10.1161/CIRCULATIONAHA.109.926394 CrossRefPubMedPubMedCentral

71.

W. Wicomb, S.T. Boyd, D.K. Cooper et al. Ex vivo functional evaluation of pig hearts subjected to 24 hours preservation by hypothermic perfusion. S. Afr. Med. J. 60, 245–248 (1981).PubMed

72.

D.K. Cooper, D. Novitzky, W.N. Wicomb et al. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. Front. Biosci. 14, 3750–3770 (2009).CrossRef

73.

D. Novitzky, Z. Mi, Q. Sun et al. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation 98, 1119–1127 (2014). https://doi.org/10.1097/TP.0000000000000187 CrossRefPubMed

74.

L.B. Cooper, C.A. Milano, M. Williams et al. Thyroid hormone use during cardiac transplant organ procurement. Clin. Transpl. 30, 1578–1583 (2016). https://doi.org/10.1111/ctr.12860 CrossRef

75.

J.G. Zaroff, B.R. Rosengard, W.F. Armstrong, et al., Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 106, 836–841 (2002). https://doi.org/10.1161/01.cir.0000025587.40373.75.CrossRefPubMed

Title: Novel uses of thyroid hormones in cardiovascular conditions
Author: Salman Razvi
Publication date: 01-10-2019
Publisher: Springer US
Keywords: Myocardial Infarction
Heart Failure
CABG
CABG
Published in: Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02050-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Thyroid hormone therapy in differentiated thyroid cancer

Diagnosis and treatment of hypothyroidism in the elderly

Thyroid hormone therapy: past, present, and future

T4 + T3 combination therapy: any progress?

Novel thyroid hormones

Thyroid hormone therapy of hypothyroidism in pregnancy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage